Stockscreener 앱 받기
0.2172
16.32%
0.0321
전일 마감가:
$0.1851
열려 있는:
$0.22
하루 거래량:
2.03M
Relative Volume:
8.74
시가총액:
$N/A
수익:
$39.55M
순이익/손실:
$-122.93M
주가수익비율:
-0.4911
EPS:
-0.4423
순현금흐름:
$-97.31M
1주 성능:
+16.32%
1개월 성능:
-51.83%
6개월 성능:
-75.91%
1년 성능:
-82.72%
1일 변동 폭
$0.2141
$0.23
1주일 범위
$0.2141
$0.23
52주 변동 폭
$0.1172
$0.23
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Compare SGMO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.2221 | 0 | 39.55M | -122.93M | -97.31M | -0.4423 |
VRTX
Vertex Pharmaceuticals Inc
|
427.66 | 107.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
621.06 | 63.21B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
813.14 | 49.89B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.82 | 38.20B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.37 | 32.17B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-12-13 | 업그레이드 | Truist | Hold → Buy |
| 2024-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2023-11-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-02-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2021-05-04 | 개시 | RBC Capital Mkts | Outperform |
| 2021-01-07 | 재개 | Guggenheim | Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-12-16 | 재개 | H.C. Wainwright | Buy |
| 2020-09-08 | 개시 | BofA Securities | Buy |
| 2020-07-07 | 개시 | SunTrust | Buy |
| 2019-08-26 | 개시 | H.C. Wainwright | Buy |
| 2018-11-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2018-10-10 | 개시 | Guggenheim | Buy |
| 2018-06-20 | 개시 | BofA/Merrill | Buy |
| 2017-11-15 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | 재개 | Jefferies | Buy |
| 2016-11-01 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2016-10-19 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-10-23 | 재개 | Jefferies | Buy |
| 2013-05-03 | 개시 | BioLogic Equity Research | Sell |
| 2011-02-23 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-07-29 | 재확인 | Wedbush | Outperform |
| 2009-10-19 | 개시 | Brean Murray | Sell |
| 2009-10-07 | 재확인 | Leerink Swann | Outperform |
| 2009-08-25 | 재확인 | JMP Securities | Mkt Outperform |
모두보기
Sangamo Therapeutics Inc 주식(SGMO)의 최신 뉴스
Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Davis Gregory D - Moomoo
Sangamo (SGMO) executive shares withheld to cover RSU tax obligations - Stock Titan
Sangamo (SGMO) SVP surrenders 4,036 shares for RSU tax withholding - Stock Titan
Sangamo (SGMO) SVP uses 4,036 shares to cover RSU tax - Stock Titan
Sangamo Therapeutics (SGMO) CEO surrenders RSU shares to cover taxes - Stock Titan
Sangamo presents primate data for prion suppressor ST-506 - BioWorld News
Sangamo Therapeutics (SGMO) reports Q1 loss, misses revenue estimates - MSN
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2026 Earnings Call Transcript - Insider Monkey
Sangamo Therapeutics Reports No Unregistered Equity Sales or Share Repurchases for the Period - TipRanks
Sangamo Therapeutics, Inc. (SGMO) Presents at 29th ASGCT Annual Meeting 2026Slideshow - Seeking Alpha
Finance Watch: Sangamo Once Again Nearing The End Of Its Cash - Citeline News & Insights
Sangamo Therapeutics | SCHEDULE 13G: Others - Moomoo
Sangamo Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (OTCMKTS:SGMO) 2026-05-15 - Seeking Alpha
Q1 2026 Sangamo Therapeutics Inc Earnings Call Transcript - GuruFocus
Sangamo Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Sangamo Therapeutics (SGMO) Q1 2026 Earnings: EPS -$0.08 vs $0.0 - GuruFocus
Sangamo Therapeutics (SGMO) Advances BLA Submission Amid OTCQB T - GuruFocus
Sangamo Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Sangamo Therapeutics Inc (SGMO) Q1 2026 Earnings Call Highlights: Progress Amidst Financial Challenges - GuruFocus
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Sangamo anticipates completing ST-920 BLA submission as early as this summer while appealing NASDAQ delisting in June - MSN
Sangamo Therapeutics earnings missed by $0.02, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Sangamo Therapeutics Q1 2026 reveals financial challenges - Investing.com Nigeria
SGMO: BLA submission for Fabry therapy advances as FDA waives need for a second confirmatory study - TradingView
SGMO: Advanced BLA submission for Fabry therapy, FDA support, and strategic capital efforts underway - TradingView
Transcript : Sangamo Therapeutics, Inc., Q1 2026 Earnings Call, May 14, 2026 - marketscreener.com
Sangamo Therapeutics | 8-K: SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2026 FINANCIAL RESULTS - Moomoo
Full Transcript: Sangamo Therapeutics Q1 2026 Earnings Call - Benzinga
Press Release: Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results - Moomoo
Sangamo Therapeutics Inc (NASDAQ:SGMO) Misses Q1 2026 Estimates, Stock Plunges 15.6% - ChartMill
SANGAMO THERAPEUTICS ($SGMO) Releases Q1 2026 Earnings - Quiver Quantitative
More on Sangamo Therapeutics - MSN
Sangamo Therapeutics Q1 2026 earnings preview - MSN
Sangamo: Q1 Earnings Snapshot - Barchart.com
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results - The Manila Times
Sangamo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Sangamo Therapeutics reports Q1 2026 net loss of $31.0M; revenues $1.4M, cash $27.6M - TradingView
TradingKey - TradingKey
Sangamo Therapeutics : Zinc finger fusions and synthetic DNA donor engineering improve the performance of reprogrammed modular integrases at the TRAC locus - marketscreener.com
Sangamo Therapeutics Announces First Quarter 2026 Earnings Call - The Manila Times
Sangamo Therapeutics (SGMO) Eps Diluted (TTM) - Zacks Investment Research
Sangamo Therapeutics, Inc.(OTCPK: SGMO) dropped from S&P TMI Index - marketscreener.com
Sangamo Therapeutics, Inc.(OTCPK: SGMO) dropped from S&P Global BMI Index - marketscreener.com
SGMO Price Today: Sangamo Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
SGMO Stock Could Be Ready for a Major Rebound as Investor Interest Grows - vocal.media
SGMO ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Sangamo Therapeutics, Inc. Shareholders Who Lost Money - ACCESS Newswire
Sangamo Therapeutics(SGMO) Stock Options Chain | Quotes & News - Moomoo
Free cash flow of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
CapEx per share of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Basic earnings per share (basic EPS) of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Gross margin % of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Sangamo Therapeutics Inc (SGMO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.48%
0.73%
자본화:
|
볼륨(24시간):